Ligand Pharmaceuticals LGND Others — Financial Royalty Assets, Net

Other product segments

Similar metrics at other companies

CEOther — Goodwill and intangible assets, net

$0—

MOAll Other — Other Intangible Assets, net

$334M-75.0%

BDXOther Intangible Assets Net

$450M-15.1%

REGNOther intangible assets—net

$1.29B+10.3%

GNTXPatents and other assets, net

$77.05M+4.7%

BSXOther intangible assets—net

$7.06B+7.5%

Questions, answered.

What is Ligand Pharmaceuticals's others — financial royalty assets, net?

Ligand Pharmaceuticals (LGND) reported others — financial royalty assets, net of $5.53M in Q1 2026.

What does others — financial royalty assets, net mean?

This metric represents the net book value of royalty-based intangible assets within the 'Others' segment, calculated as the gross carrying value minus any applicable valuation allowances. It provides a current, risk-adjusted snapshot of the economic value the company expects to derive from these specific pharmaceutical partnerships and licensing arrangements. Investors use this figure to assess the tangible value of the segment's portfolio and its potential to contribute to future royalty revenue.